Obesity Featured Articles

  1. The FDA Just Rewrote The Rules For Clinical Trials. Here's What It Means For RTSM. 7/30/2026

    Learn how evolving trial designs are changing RTSM requirements and driving demand for greater flexibility, traceability, and execution quality.

  2. When "Everything" Is The Pain Point: Rethinking RTSM For Real-World Use 7/30/2026

    RTSM friction often comes from complexity, limited flexibility, and siloed data. Discover approaches that improve visibility, forecasting, and operational efficiency across clinical trials.

  3. The Agentic AI Readiness Myths Costing Sponsors Time 7/30/2026

    Many clinical organizations believe they must clean data and unify systems before adopting agentic AI. New approaches show teams can start now, create value faster, and improve readiness as they scale.

  4. Why Trial Expertise Makes Or Breaks Clinical AI 7/30/2026

    What makes AI effective in clinical trials? See how a top 5 pharma sponsor achieved a 62% reduction in CRA task time and 99% document classification accuracy by prioritizing clinical fluency.

  5. Real-Time Trials Need Real-Time Data You Can Trust 7/30/2026

    The FDA just kicked off real-time clinical trials with AstraZeneca and Amgen. But speed means nothing if the underlying data is inconsistent.

  6. Agentic AI Is Reshaping Clinical Monitoring And The CRA Role Again 7/30/2026

    See why this isn't about replacing CRAs, but freeing them from the admin grind so they can focus on judgment, site relationships, and the work that actually moves trials forward.

  7. What Controlled Immune Challenges Reveal Before Patient Studies Begin 7/30/2026

    Controlled immune challenges can reveal target engagement and pharmacology before efficacy is measurable, supporting earlier and more informed development decisions.

  8. Making Early Decisions In Psychiatric Drug Development 7/30/2026

    Quantitative PD measures provide objective evidence of target engagement, support dose selection, strengthen early go/no-go decisions, and help reduce development risk in psychiatric

  9. How NeuroKit® Helps Avoid False Negatives in Early CNS Development 7/30/2026

    Detecting subtle CNS effects early can reduce false negatives. Sensitive assessments strengthen confidence in pharmacodynamic signals and dose selection.

     

  10. EU Clinical Trial Regulation Timelines: Shorter Than Many Expect 7/30/2026

    The EU CTR rewards early planning. Strong documentation, regulatory readiness, and aligned partners can help accelerate approvals and reduce delays.